^
2d
IO biomarker
|
PD-L1 (Programmed death ligand 1) • MRE11A (MRE11 homolog, double strand break repair nuclease)
16d
HER-2 (Human epidermal growth factor receptor 2) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • TSC1 (TSC complex subunit 1) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
16d
PAX8 (Paired box 8)
16d
PAX8 (Paired box 8)
29d
Checkpoint inhibition • IO biomarker • Circulating tumor DNA
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA (Breast cancer early onset)
|
PIK3CA mutation • BRCA mutation
1m
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin-dependent kinase inhibitor 2A)
2ms
IO biomarker
|
PD-L1 (Programmed death ligand 1) • MRE11A (MRE11 homolog, double strand break repair nuclease)
3ms
FOXA1 (Forkhead Box A1) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • GATA3 (GATA binding protein 3)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
5ms
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
Truseltiq (infigratinib)
7ms
Pan tumor
|
TMB (Tumor Mutational Burden) • mTOR (Mechanistic target of rapamycin kinase) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
|
TMB-H • TSC1 mutation • MTOR mutation • TSC2 mutation
|
everolimus
7ms
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FGFR3 (Fibroblast growth factor receptor 3) • RB1 (RB Transcriptional Corepressor 1) • MTAP (Methylthioadenosine Phosphorylase)
|
TMB-H
|
PD-L1 IHC 22C3 pharmDx
11ms
PAX8 (Paired box 8)
12ms
Clinical
|
FGF (Fibroblast Growth Factor)
1year
PD(L)-1 Biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • PD-1 (Programmed cell death 1)
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin)
1year
Clinical • PD(L)-1 Biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • PD-1 (Programmed cell death 1)
|
FGFR3 mutation • FGFR3 fusion
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin)
over1year
PD-L1 (Programmed death ligand 1)
over1year
Checkpoint inhibition
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR2 mutation • FGFR3 mutation
|
Balversa (erdafitinib)
over1year
Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression
|
Keytruda (pembrolizumab)
almost2years
BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)